RT Journal Article
T1 T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease.
A1 Alcázar-Navarrete, Bernardino
A1 Díaz-Lopez, Jose Manuel
A1 García-Flores, Paula
A1 Ortega-Antelo, Marina
A1 Aguilar-Cruz, Ivan
A1 Ruiz-Rodríguez, Oliverio
A1 Santiago-Diaz, Pablo
A1 Romero Palacios, Pedro José
K1 Biomarkers
K1 COPD
K1 Eosinophil
K1 FeNO
K1 Type 2 inflammation
AB Type 2 (T2) biomarkers such as blood eosinophil count (BEC) and FeNO have been related to a higher risk of exacerbations in COPD. It is unknown whether combining these biomarkers could be useful in forecasting COPD exacerbations. COPD patients were enrolled in this prospective, multicenter, observational study and followed up for 1 year, during which BEC were analysed at baseline (V0) while FeNO analyses were performed at baseline (V0), 6 months (V1) and 12 months (V2). The risk of moderate or severe exacerbation during follow up was assessed by Cox regression analysis, and the predictive capacity of both measurements was assessed by ROC curves and the DeLong test. Statistical significance was assumed at P Of the 322 COPD patients initially recruited, 287 were followed up. At baseline, 28.0% were active smokers, and experienced moderate airflow limitation (mean FEV1 56.4%±17.0% predicted). Patients with at least one elevated T2 biomarker (n=125, 42.5%) were at increased risk of COPD exacerbation (HR 1.75, 95% CI 1.25-2.45, P=.001) and of shorter time to first COPD exacerbation. There was no difference between BEC and FeNO regarding the predictive capacity for moderate to severe exacerbation (AUC 0.584 vs 0.576, P=.183) but FeNO predicted severe episodes more accurately than BEC (AUC 0.607 vs 0.539, P Both eosinophil count and FeNO have limited utility for predicting COPD exacerbations. Combining these T2 biomarkers could enhance the detection of future COPD exacerbations.
YR 2021
FD 2021-11-27
LK http://hdl.handle.net/10668/22003
UL http://hdl.handle.net/10668/22003
LA en
LA es
DS RISalud
RD Apr 9, 2025